STIM - NASDAQ
Neuronetics, Inc.
$1.39
+2.3%Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
At a Glance
Live Snapshotstim
Cash and Short Term Investments
Last Annual Value
34.36M
3-Year CAGR
-22%
5-Year CAGR
-8%
10-Year CAGR
7%
Neuronetics, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Neuronetics, Inc. NASDAQ:STIM | 34.36M | -17.2% | -18.6% | 7.3% | |
 Aclaris Therapeutics, Inc. NASDAQ:ACRS | 90.75M | -8.7% | -13.9% | -6.3% | |
 Health Catalyst, Inc. NASDAQ:HCAT | 95.73M | -33.0% | -26.5% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 226.69M | 4.2% | -17.5% | N/A | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 155.55M | 33.4% | 11.3% | 14.2% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 20.95M | -36.3% | -43.9% | -17.5% | |
 OraSure Technologies, Inc. NASDAQ:OSUR | 199.28K | -91.2% | -73.5% | -47.3% | |
 Perspective Therapeutics, Inc. AMEX:CATX | 144.74M | 150.2% | 19.1% | 32.1% | |
 Codexis, Inc. NASDAQ:CDXS | 78.21M | 6.3% | -7.7% | 15.1% | |
 Atlantic International Corp. NASDAQ:ATLN | 81.13K | -60.9% | -61.8% | -9.0% | |
 OmniAb, Inc. NASDAQ:OABI | 54.02M | -14.7% | N/A | N/A |
Neuronetics, Inc. Fair Value Envelope
Related Guides
Continue your STIM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.